Skip to content
OnKommon
An oncologist in conversation with a patient in a consulting room.

For doctors & clinical teams

Molecular findings, context and evidence —in one structured view.

Twin organises the evidence. You review it, sign it and decide. Explore the pathways, the report and the sign-off sequence — and how AVATAR research collaboration differs.
Request a Twin demonstrationSee the report

Doctors · storyline

OnKommon gives the oncologist superpowers.

Six ways your practice changes when every patient has a Twin.

01 / 06 · See everything

Every result, in context.

Molecular findings, clinical history, imaging, treatment exposure and the evidence — brought into one structured view instead of a pile of PDFs.
How Twin works →

The clinical problem

The picture arrives in pieces — and keeps moving.

  • 01

    Fragmented reports

    Molecular results, imaging and history arrive in separate documents at different times.

  • 02

    Differing sample types

    Tissue, plasma, blood and bone marrow answer different questions with different limits.

  • 03

    Variant evidence

    Separating drivers from background, and strong evidence from weak, takes time.

  • 04

    Changing context

    New results, new evidence and treatment changes keep shifting the picture.

What you receive

Five components.One report.

Source data kept apart from interpretation, evidence strength and uncertainty stated, options offered for evaluation — and a longitudinal view that continues.

Reports & outputs Evidence & uncertainty

OnKommon Twin · Structured report

  1. 01

    Executive molecular summary

    Overview, key findings, clinical context.

    Distinguish source data from interpretation.

  2. 02

    Molecular findings

    Genomic and biomarker findings, in context.

    State coverage, evidence strength and uncertainty.

  3. 03

    Treatment options

    Evidence-informed options to evaluate.

    Options to evaluate — never phrased as autonomous prescriptions.

  4. 04

    Clinical-trial matches

    Trials matched to patient and biomarkers.

    A potential match is not eligibility or enrolment confirmation.

  5. 05

    Longitudinal view

    Findings and change, over time.

    Show only updates supported by actual inputs and cadence.

For review and signature by the treating oncologist

Clinical authority

You review it.You sign it.You decide.

Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board. Twin informs your judgement; it never replaces it.
The KPCIRC sign-off process
A gold fountain pen resting on a white surface.

Structured report

Treating oncologistReviewed & signed

Two offerings

Explore each separately

Their intended uses and evidence limits are different — and stay visibly different.

Longitudinal intelligence

OnKommon Twin

Pathways, evidence-linked findings, trial intelligence and a longitudinal view across 21 layers — reviewed and signed by you.

Twin for clinicians

Exploratory research

OnKommon AVATAR

For eligible solid-tumour WES cases: computational and experimental evidence, side by side, reviewed by KPCIRC's Molecular Tumour Board.

AVATAR for clinicians

Pathways

Four testing pathways, then Twin tracks

Compare testing & tracking
Blood cancers

Blood 600

Twin Blood 600

DNA and RNA together, from blood or bone marrow.

Explore this pathway
Solid tumours

Exome / WES

Twin Exome

Whole-exome sequencing (WES) across every protein-coding gene.

Explore this pathway
Solid tumours

Liquid 523

Twin Liquid

523-gene ctDNA panel from plasma. Hereditary testing included for germline filtering.

Explore this pathway
Solid tumours

Tissue 335

Twin Tissue

335-gene panel. FFPE or fresh tumour tissue.

Explore this pathway

Clinical governance

Clinical ownership

The treating oncologist owns everything.

“The Clinical Twin belongs to the treating oncologist and their patient.” OnKommon organises the evidence; the oncologist reviews it, signs it and makes every decision.

See the KPCIRC sign-off process

  • You decide

    Clinical authority stays with you.

  • You review and sign

    Every report reviewed and signed by you.

  • You control access

    Access follows your approved workflow.

  • The Twin evolves with you

    New evidence can prompt reassessment.

For clinicians

Go deeper

FAQs

Questions clinicians ask

Where does Twin sit in my decision-making?
Twin gives you structured findings to review. You sign every report, clinical authority stays with you, and the signed report is taken to KPCIRC's Molecular Tumour Board.
How are variants classified?
Somatic findings are tiered by the strength of their clinical evidence, and germline findings are classified for pathogenicity — each in its own framework, with the evidence shown.
How do I refer a patient?
Request a service discussion. The OnKommon team sets up secure case intake for your practice, so patient identifiers and files never travel through public website forms.
Who controls access to my patient's Twin?
The Clinical Twin belongs to the treating oncologist and their patient, and access follows your approved workflow.
What are the turnaround times and sample requirements?
They depend on the pathway. The OnKommon team shares the requirements and timeline for each case when the test is ordered.

Next step

Request a Twin demonstration

See the pathways, the report and the sign-off sequence with the team. Please don't include patient information — secure case intake is arranged separately.

Before you write: Please do not include patient names, identifiers, reports, genomic files or any other health information. Secure case intake is arranged separately.

Only if you prefer a call.

What would you like the demonstration to cover?

Preferred contact method *

Goes to: Clinical partnerships team. No response time is promised until one is approved.

Continue the journey

For hospitals

Precision oncology, in your own corridors.

→